According to recent foreign media reports, Blackstone Life Sciences has signed a $455 million collaboration agreement with Boston Scientific to jointly fund the development of Boston Scientific's next-generation micro heart pump system.
It is understood that Boston Scientific's next-generation micro heart pump system is part of the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System project. This device is designed to increase cardiac output, improve blood flow, and treat cardiogenic shock caused by acute myocardial infarction.
Cardiogenic shock is a life-threatening condition in which the heart is unable to pump enough blood to supply the brain and other organs, manifesting as a heart attack or other heart problems. Despite advancements in treatment, its mortality rate remains high.
According to Blackstone, the Vitalyst system was developed to address core unmet needs of critically ill cardiogenic patients, with the goal of improving efficacy, safety, and ease of use for physicians treating these patients.
Dr. Nicholas Galakatos, Global Head of Life Sciences at Blackstone, stated that Boston Scientific has established a leading cardiovascular business with deep expertise in developing and commercializing transformative technologies for patients and physicians. He also affirmed the Vitalyst system, stating its potential to improve the efficacy and safety of existing mechanical circulatory support technologies.
It is worth noting that this is the first time Boston Scientific and Blackstone have jointly funded the development of Boston Scientific products. However, this collaboration is similar to Blackstone's 2020 partnership with Medtronic to support its diabetes research and development program.
Looking at Boston Scientific's product portfolio, we can see that its product layout is quite comprehensive. It has launched 6,850 products in the US and 336 products in China. Boston Scientific also has corresponding layouts in many emerging and promising sectors, especially in the PFA sector, which has been popular in recent years, where Boston Scientific is in a relatively leading position.
However, Boston Scientific has faced numerous challenges this year. In August, it announced that its information technology systems had been attacked, causing disruption to its global business operations and indicating that it might not be able to achieve its previously provided full-year financial targets. Subsequently, in its Q2 financial report, the growth of its two major businesses, Watchman and Electrophysiology, was weak, increasing the pressure, and it was expected that the two businesses would not improve in the second half of the year.
Due to multiple pressures, Boston Scientific plans to initiate an organizational restructuring starting January 1st next year, splitting its cardiovascular group into two segments: Interventional Therapies and Rhythm Solutions, together with the existing MedSurg, forming three major business segments.
Under the new structure, the Interventional Therapies segment, encompassing interventional cardiology, vascular therapy, and interventional oncology and embolization, will be led by current President of Interventional Therapies, Lance Bates. This segment will also absorb Penumbra's stroke-focused business following the $14.5 billion acquisition of Penumbra.

Source: https://news.yaozh.com/archive/49354.html